abrdn Life Sciences Investors $HQL Stake Lowered by 1607 Capital Partners LLC

1607 Capital Partners LLC trimmed its stake in shares of abrdn Life Sciences Investors (NYSE:HQL) by 24.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 122,170 shares of the company’s stock after selling 39,801 shares during the quarter. 1607 Capital Partners LLC owned about 0.42% of abrdn Life Sciences Investors worth $1,895,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Geneos Wealth Management Inc. increased its position in abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after buying an additional 1,529 shares during the period. Cornerstone Advisors LLC acquired a new stake in shares of abrdn Life Sciences Investors in the 3rd quarter worth about $175,000. Clough Capital Partners L P bought a new stake in abrdn Life Sciences Investors in the 2nd quarter valued at about $318,000. Stephens Inc. AR lifted its position in abrdn Life Sciences Investors by 12.4% in the 3rd quarter. Stephens Inc. AR now owns 23,869 shares of the company’s stock valued at $370,000 after purchasing an additional 2,638 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its stake in abrdn Life Sciences Investors by 28.8% during the 2nd quarter. Osaic Holdings Inc. now owns 30,459 shares of the company’s stock valued at $390,000 after purchasing an additional 6,802 shares during the period. Institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Stock Performance

NYSE HQL opened at $16.38 on Friday. abrdn Life Sciences Investors has a 52 week low of $10.55 and a 52 week high of $17.80. The company has a 50-day moving average price of $16.80 and a two-hundred day moving average price of $16.36.

abrdn Life Sciences Investors Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Friday, February 20th will be given a dividend of $0.56 per share. This is a boost from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50. This represents a $2.24 annualized dividend and a dividend yield of 13.7%. The ex-dividend date is Friday, February 20th.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.